GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stem Cells Spin SA (WAR:SCS) » Definitions » Cash Flow from Financing

Stem Cells Spin (WAR:SCS) Cash Flow from Financing : zł-0.07 Mil (TTM As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Stem Cells Spin Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2024, Stem Cells Spin paid zł0.00 Mil more to buy back shares than it received from issuing new shares. It spent zł0.01 Mil paying down its debt. It paid zł0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received zł0.00 Mil from paying cash dividends to shareholders. It received zł0.00 Mil on other financial activities. In all, Stem Cells Spin spent zł0.01 Mil on financial activities for the three months ended in Dec. 2024.


Stem Cells Spin Cash Flow from Financing Historical Data

The historical data trend for Stem Cells Spin's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stem Cells Spin Cash Flow from Financing Chart

Stem Cells Spin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.17 -0.10 -0.47 -0.15 -0.05

Stem Cells Spin Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.08 0.01 - -0.01

Stem Cells Spin Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Stem Cells Spin's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Stem Cells Spin's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stem Cells Spin  (WAR:SCS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Stem Cells Spin's issuance of stock for the three months ended in Dec. 2024 was zł0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Stem Cells Spin's repurchase of stock for the three months ended in Dec. 2024 was zł0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Stem Cells Spin's net issuance of debt for the three months ended in Dec. 2024 was zł-0.01 Mil. Stem Cells Spin spent zł0.01 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Stem Cells Spin's net issuance of preferred for the three months ended in Dec. 2024 was zł0.00 Mil. Stem Cells Spin paid zł0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Stem Cells Spin's cash flow for dividends for the three months ended in Dec. 2024 was zł0.00 Mil. Stem Cells Spin received zł0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Stem Cells Spin's other financing for the three months ended in Dec. 2024 was zł0.00 Mil. Stem Cells Spin received zł0.00 Mil on other financial activities.


Stem Cells Spin Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Stem Cells Spin's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Stem Cells Spin Business Description

Traded in Other Exchanges
N/A
Address
Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.